Hycamtin (Topotecan Injection) and Paraplatin NovaPlus
Determining the interaction of Hycamtin (Topotecan Injection) and Paraplatin NovaPlus and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using CARBOplatin together with topotecan can increase the effects of either medication. Watch for the potential risk for a severe decrease in white blood cells and bone marrow function must be closely monitored. If your doctor prescribes these medications together, you may need a dose adjustment or special tests to safely take both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR CLOSELY: Topotecan combined with a platinum agent may produce synergistic cytotoxicity against some germ cell cancers. However, myelosuppression may also be more severe. In a reported study where patients were given cisplatin 50 mg/m2 and topotecan 1.25 mg/m2/day for 5 days, one of three patients had severe neutropenia for 12 days and a second patient died with neutropenic sepsis. The interaction appears to be sequence-dependent. Specifically, coadministration of a platinum agent on day 1 of topotecan dosing required lower dosages of each agent compared to coadministration on day 5 of the topotecan dosing schedule.
MANAGEMENT: There are currently insufficient data to recommend a safe and effective regimen for topotecan in combination with a platinum agent. Clinicians should recognize the potential risk for severe neutropenia if these agents are used together, and bone marrow function must be closely monitored. Lower dosages of each agent may be required.
- Chou TC, Motzer RJ, Tong Y, Bosl GJ "Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design." J Natl Cancer Inst 86 (1994): 1517-24
- "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
- Rowinsky E, Grochow L, Kaufmann S, Bowling K, Sartorius S, Chen T, Lubejko B, Ettinger D, Peereboom D, Donehower R "Sequence-dependent effects of topotecan (T) and cisplatin (C) in a Phase I and pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 13 (1994): a3611994
Generic Name: topotecan
Brand name: Hycamtin
Synonyms: Hycamtin (oral/injection), Hycamtin
Generic Name: carboplatin
Brand name: Paraplatin, CARBOplatin Novaplus
Synonyms: Paraplatin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Hycamtin (Topotecan Injection)-Parathyroid hormone
- Hycamtin (Topotecan Injection)-Parathyroid hormone Subcutaneous
- Hycamtin (Topotecan Injection)-Parcopa
- Hycamtin (Topotecan Injection)-Paregoric
- Hycamtin (Topotecan Injection)-Paremyd
- Hycamtin (Topotecan Injection)-Paremyd Ophthalmic
- Paraplatin NovaPlus-Hycamtin Capsules
- Paraplatin NovaPlus-Hycamtin Intravenous
- Paraplatin NovaPlus-Hycamtin oral/injection
- Paraplatin NovaPlus-Hycet
- Paraplatin NovaPlus-Hycodan
- Paraplatin NovaPlus-Hycodan Oral